Compare MLCO & AVDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLCO | AVDL |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | Hong Kong | Ireland |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.1B |
| IPO Year | 2006 | 1996 |
| Metric | MLCO | AVDL |
|---|---|---|
| Price | $6.31 | $21.63 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 8 |
| Target Price | $9.42 | ★ $19.14 |
| AVG Volume (30 Days) | ★ 2.7M | 1.5M |
| Earning Date | 02-12-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | ★ $5,061,044,000.00 | $248,517,000.00 |
| Revenue This Year | $13.28 | $65.47 |
| Revenue Next Year | $2.61 | $30.88 |
| P/E Ratio | $25.06 | ★ N/A |
| Revenue Growth | 11.46 | ★ 79.88 |
| 52 Week Low | $4.55 | $6.38 |
| 52 Week High | $10.15 | $23.57 |
| Indicator | MLCO | AVDL |
|---|---|---|
| Relative Strength Index (RSI) | 42.53 | 62.61 |
| Support Level | $5.98 | $21.52 |
| Resistance Level | $6.53 | $21.65 |
| Average True Range (ATR) | 0.23 | 0.07 |
| MACD | 0.09 | -0.00 |
| Stochastic Oscillator | 65.55 | 73.81 |
Melco Resorts & Entertainment is one of only six licensed casino operators in Macao. It operates Altira, a complex focused on premium customers; City of Dreams, an integrated resort in Cotai serving both mass-market and premium patrons; and Mocha Clubs' electronic gaming machines. The company also has a majority interest in Studio City, which opened in 2015. Outside Macao, Melco owns City of Dreams Manila in the Philippines and City of Dreams Mediterranean in Cyprus. The business mix in terms of adjusted EBITDA was about 81% from Macao, with the rest largely from the Philippines as of 2024.
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.